Eyes On Dainippon’s Phase III Stem Cell Cancer Drug – Japan Earnings Profiles
This article was originally published in PharmAsia News
Executive Summary
Japan’s earnings season highlights new R&D and launch strategies for Mitsubishi Tanabe, Astellas and Takeda.
You may also be interested in...
Canagliflozin Should Have Limitations Based On Renal Function, Panel Says
Several advisory committee members on both sides of a 10-5 vote voiced concern about using Janssen’s diabetes drug in patients with moderate renal impairment.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.